El primer fármaco para el que se ha elaborado un nuevo informe es Blenrep (belantamab mafodotina, GSK), un medicamento que se ...

Als Teil des Eidgenössischen Departements des Innern ist das BAG verantwortlich für die Gesundheit der Bevölkerung, entwickelt die schweizerische Gesundheitspolitik und setzt sich für ein langfristig ...

Aiming to “bend the curve toward longer disease-free survival” with improved safety in non-muscle-invasive bladder cancer (NMIBC), Tyra Biosciences Inc. CEO Todd Harris said the company has settled on ...

Tyra aimed to avoid the toxicity of J&J's Balversa by designing dabogratinib to be more selective for FGFR. (Getty Images) Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladder ...

The last time I spoke about Tyra Biosciences (TYRA), it was with a Seeking Alpha article entitled "Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point." With respect to this ...

Natco Pharma has received tentative approval from the US Food and Drug Administration (USFDA) for Erdafitinib, a generic version of Balversa by Janssen Biotech Inc. The Hyderabad-based Natco’s ...

L’Agenzia Italiana del Farmaco definisce la rimborsabilità di undici medicinali, tra cui Hemgenix, trattamento one shot per l’emofilia B. Passi avanti nel trattamento delle malattie rare e delle ...

Erdafitinib (Balversa, Johnson & Johnson) is indicated for 'the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations ...

Erdafitinib (Balversa) is available on the NHS. It is a possible treatment for urothelial cancer in adults when the cancer: is unresectable (cannot be surgically removed) or metastatic (has spread to ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Membership today. A groundbreaking targeted treatment for the most common type of bladder cancer ...

The first targeted drug for a common form of bladder cancer that can be taken at home has been backed for NHS use, offering hope of simpler treatment to hundreds of patients in England. The oral drug ...

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration Balversa (erdafitinib) has been recommended for use on the NHS as the first and only ...